Highlighting the Dystonic Phenotype Related to GNAO1.


Journal

Movement disorders : official journal of the Movement Disorder Society
ISSN: 1531-8257
Titre abrégé: Mov Disord
Pays: United States
ID NLM: 8610688

Informations de publication

Date de publication:
07 2022
Historique:
received: 17 03 2022
accepted: 21 03 2022
pubmed: 21 6 2022
medline: 23 7 2022
entrez: 20 6 2022
Statut: ppublish

Résumé

Most reported patients carrying GNAO1 mutations showed a severe phenotype characterized by early-onset epileptic encephalopathy and/or chorea. The aim was to characterize the clinical and genetic features of patients with mild GNAO1-related phenotype with prominent movement disorders. We included patients diagnosed with GNAO1-related movement disorders of delayed onset (>2 years). Patients experiencing either severe or profound intellectual disability or early-onset epileptic encephalopathy were excluded. Twenty-four patients and 1 asymptomatic subject were included. All patients showed dystonia as prominent movement disorder. Dystonia was focal in 1, segmental in 6, multifocal in 4, and generalized in 13. Six patients showed adolescence or adulthood-onset dystonia. Seven patients presented with parkinsonism and 3 with myoclonus. Dysarthria was observed in 19 patients. Mild and moderate ID were present in 10 and 2 patients, respectively. We highlighted a mild GNAO1-related phenotype, including adolescent-onset dystonia, broadening the clinical spectrum of this condition. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Sections du résumé

BACKGROUND
Most reported patients carrying GNAO1 mutations showed a severe phenotype characterized by early-onset epileptic encephalopathy and/or chorea.
OBJECTIVE
The aim was to characterize the clinical and genetic features of patients with mild GNAO1-related phenotype with prominent movement disorders.
METHODS
We included patients diagnosed with GNAO1-related movement disorders of delayed onset (>2 years). Patients experiencing either severe or profound intellectual disability or early-onset epileptic encephalopathy were excluded.
RESULTS
Twenty-four patients and 1 asymptomatic subject were included. All patients showed dystonia as prominent movement disorder. Dystonia was focal in 1, segmental in 6, multifocal in 4, and generalized in 13. Six patients showed adolescence or adulthood-onset dystonia. Seven patients presented with parkinsonism and 3 with myoclonus. Dysarthria was observed in 19 patients. Mild and moderate ID were present in 10 and 2 patients, respectively.
CONCLUSION
We highlighted a mild GNAO1-related phenotype, including adolescent-onset dystonia, broadening the clinical spectrum of this condition. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Identifiants

pubmed: 35722775
doi: 10.1002/mds.29074
pmc: PMC9545634
doi:

Substances chimiques

GNAO1 protein, human 0
GTP-Binding Protein alpha Subunits, Gi-Go EC 3.6.5.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1547-1554

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

© 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Références

Genet Med. 2019 Mar;21(3):553-563
pubmed: 29997391
Mov Disord. 2021 May;36(5):1086-1103
pubmed: 33502045
Nat Genet. 2013 Jan;45(1):88-92
pubmed: 23222958
Pediatr Neurol. 2016 Jun;59:81-4
pubmed: 27068059
Am J Hum Genet. 2013 Sep 5;93(3):496-505
pubmed: 23993195
Expert Rev Neurother. 2021 Jan;21(1):81-97
pubmed: 33089715
J Neurol Sci. 2020 Apr 15;411:116710
pubmed: 32044685
Parkinsonism Relat Disord. 2020 May;74:50-56
pubmed: 32334381
Am J Hum Genet. 2020 Aug 6;107(2):352-363
pubmed: 32693025
J Neurosci. 2004 Aug 4;24(31):7007-14
pubmed: 15295036
Neurol Genet. 2017 Mar 21;3(2):e143
pubmed: 28357411
Neurogenetics. 2020 Jan;21(1):67-72
pubmed: 31823155
Neurobiol Dis. 2018 Aug;116:131-141
pubmed: 29758257
Cell Rep. 2021 Feb 2;34(5):108718
pubmed: 33535037
Brain. 2020 Dec 5;143(11):3242-3261
pubmed: 33150406
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Epilepsia. 2019 Mar;60(3):406-418
pubmed: 30682224
Mov Disord. 2019 Oct;34(10):1516-1527
pubmed: 31216378
Mov Disord. 2019 Jun;34(6):923-924
pubmed: 30964956
Parkinsonism Relat Disord. 2019 Apr;61:19-25
pubmed: 30642806
Neurogenetics. 2022 Apr;23(2):129-135
pubmed: 35147852
Hum Mutat. 2015 Oct;36(10):928-30
pubmed: 26220891
Front Genet. 2019 Oct 29;10:1026
pubmed: 31737037
J Child Neurol. 2018 May;33(6):413-416
pubmed: 29661126
Am J Hum Genet. 2012 Dec 7;91(6):1041-50
pubmed: 23200863
J Child Neurol. 2016 Feb;31(2):211-4
pubmed: 26060304
Eur J Med Genet. 2020 Jun;63(6):103878
pubmed: 32045705
J Neurol Sci. 2018 Aug 15;391:31-39
pubmed: 30103967

Auteurs

Thomas Wirth (T)

Département de Neurologie, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, Strasbourg.
Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France.
Institut de Génétique et de Biologie Moléculaire et Cellulaire, Illkirch, France.

Giacomo Garone (G)

University Hospital Pediatric Department, IRCCS Bambino Gesù Children's Hospital, University of Rome Tor Vergata, Rome, Italy.
Movement Disorders Clinic, Department of Neurosciences, Bambino Gesù Children's Hospital, Rome, Italy.

Manju A Kurian (MA)

Molecular Neurosciences, Developmental Neurosciences, UCL Great Ormond Street Institute of Child Health, London, United Kingdom.

Amélie Piton (A)

Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France.
Institut de Génétique et de Biologie Moléculaire et Cellulaire, Illkirch, France.
Laboratoire de diagnostic génétique, Nouvel Hôpital Civil, Hôpitaux universitaires de Strasbourg, Strasbourg, France.

Francisca Millan (F)

GeneDx, Gaithersburg, Maryland, USA.

Aida Telegrafi (A)

GeneDx, Gaithersburg, Maryland, USA.

Nathalie Drouot (N)

Institut de Génétique et de Biologie Moléculaire et Cellulaire, Illkirch, France.

Gabrielle Rudolf (G)

Département de Neurologie, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, Strasbourg.
Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France.
Institut de Génétique et de Biologie Moléculaire et Cellulaire, Illkirch, France.

Jamel Chelly (J)

Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France.
Institut de Génétique et de Biologie Moléculaire et Cellulaire, Illkirch, France.
Laboratoire de diagnostic génétique, Nouvel Hôpital Civil, Hôpitaux universitaires de Strasbourg, Strasbourg, France.

Warren Marks (W)

Cook Children's Medical Centre, Fort Worth, Texas, USA.

Lydie Burglen (L)

Centre de Référence des Malformations et Maladies Congénitales du Cervelet, Département de Génétique et Embryologie Médicale, APHP, Hôpital Trousseau, Paris, France.

Diane Demailly (D)

Département de Neurochirurgie, Unité des Pathologies Cérébrales Résistantes, Unité de Recherche sur les Comportements et Mouvements Anormaux, Hôpital Gui de Chauliac, Centre Hospitalier Régional Montpellier, Montpellier, France.

Phillipe Coubes (P)

Département de Neurochirurgie, Unité des Pathologies Cérébrales Résistantes, Unité de Recherche sur les Comportements et Mouvements Anormaux, Hôpital Gui de Chauliac, Centre Hospitalier Régional Montpellier, Montpellier, France.

Mayte Castro-Jimenez (M)

Service de Neurologie, Department of Clinical Neurosciences, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.

Sylvie Joriot (S)

Department of Paediatric Neurology, University Hospital of Lille, Lille, France.

Jamal Ghoumid (J)

Univ. Lille, ULR7364 RADEME, CHU Lille, Clinique de Génétique Guy Fontaine, Lille, France.

Jérémie Belin (J)

Service de neurologie, CHU Tours, Tours, France.

Jean-Marc Faucheux (JM)

Service de neurologie, Hôpital d'Agen, Agen, France.

Lubov Blumkin (L)

Pediatric Movement Disorders Clinic, Pediatric Neurology Unit, Wolfson Medical Center, Holon, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.

Mariam Hull (M)

Pediatric Movement Disorders Clinic, Blue Bird Circle Clinic for Pediatric Neurology, Section of Pediatric Neurology and Developmental Neuroscience, Texas Children's Hospital, Houston, Texas, USA.

Mered Parnes (M)

Pediatric Movement Disorders Clinic, Blue Bird Circle Clinic for Pediatric Neurology, Section of Pediatric Neurology and Developmental Neuroscience, Texas Children's Hospital, Houston, Texas, USA.

Claudia Ravelli (C)

Sorbonne Université, Service de Neuropédiatrie-Pathologie du développement, centre de référence neurogénétique, Hôpital Trousseau AP-HP.SU, FHU I2D2, Paris, France.

Gaëtan Poulen (G)

Département de Neurochirurgie, Unité des Pathologies Cérébrales Résistantes, Unité de Recherche sur les Comportements et Mouvements Anormaux, Hôpital Gui de Chauliac, Centre Hospitalier Régional Montpellier, Montpellier, France.

Nadège Calmels (N)

Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France.
Institut de Génétique et de Biologie Moléculaire et Cellulaire, Illkirch, France.
Laboratoire de diagnostic génétique, Nouvel Hôpital Civil, Hôpitaux universitaires de Strasbourg, Strasbourg, France.

Andrea H Nemeth (AH)

Oxford University Hospitals National Health Service Foundation Trust and University of Oxford, Oxford, United Kingdom.

Martin Smith (M)

Oxford University Hospitals National Health Service Foundation Trust and University of Oxford, Oxford, United Kingdom.

Angela Barnicoat (A)

Department of Clinical Genetics, Great Ormond Street Hospital, London, United Kingdom.

Claire Ewenczyk (C)

Sorbonne Université/Inserm U1127/CNRS UMR 7225/Institut du Cerveau, Paris, France.
Service de neurologie, Hôpital la Pitié Salpêtrière, Sorbonne Université, Paris, France.

Aurélie Méneret (A)

Sorbonne Université/Inserm U1127/CNRS UMR 7225/Institut du Cerveau, Paris, France.
Service de neurologie, Hôpital la Pitié Salpêtrière, Sorbonne Université, Paris, France.

Emmanuel Roze (E)

Sorbonne Université/Inserm U1127/CNRS UMR 7225/Institut du Cerveau, Paris, France.
Service de neurologie, Hôpital la Pitié Salpêtrière, Sorbonne Université, Paris, France.

Boris Keren (B)

Sorbonne Université/Inserm U1127/CNRS UMR 7225/Institut du Cerveau, Paris, France.
Service de neurologie, Hôpital la Pitié Salpêtrière, Sorbonne Université, Paris, France.

Cyril Mignot (C)

Sorbonne Université/Inserm U1127/CNRS UMR 7225/Institut du Cerveau, Paris, France.
Service de neurologie, Hôpital la Pitié Salpêtrière, Sorbonne Université, Paris, France.

Christophe Beroud (C)

Aix Marseille Université, INSERM, MMG, Bioinformatics & Genetics, Marseille, France.

Fernando Acosta (F)

Cook Children's Medical Centre, Fort Worth, Texas, USA.

Catherine Nowak (C)

The Feingold Center for Children, Division of Genetics and Genomics, Boston Children's Hospital, Boston, Massachusetts, USA.

William G Wilson (WG)

Department of Pediatrics, University of Virginia, Charlottesville, Virginia, USA.

Dora Steel (D)

Molecular Neurosciences, Developmental Neurosciences, UCL Great Ormond Street Institute of Child Health, London, United Kingdom.

Alessandro Capuano (A)

Movement Disorders Clinic, Department of Neurosciences, Bambino Gesù Children's Hospital, Rome, Italy.

Marie Vidailhet (M)

Sorbonne Université/Inserm U1127/CNRS UMR 7225/Institut du Cerveau, Paris, France.
Service de neurologie, Hôpital la Pitié Salpêtrière, Sorbonne Université, Paris, France.

Jean-Pierre Lin (JP)

Children's Neurosciences Department, Evelina London Children's Hospital, Guy's and St Thomas NHS Foundation Trust, London, United Kingdom.

Christine Tranchant (C)

Département de Neurologie, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, Strasbourg.
Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France.
Institut de Génétique et de Biologie Moléculaire et Cellulaire, Illkirch, France.

Laura Cif (L)

Département de Neurochirurgie, Unité des Pathologies Cérébrales Résistantes, Unité de Recherche sur les Comportements et Mouvements Anormaux, Hôpital Gui de Chauliac, Centre Hospitalier Régional Montpellier, Montpellier, France.

Diane Doummar (D)

Sorbonne Université, Service de Neuropédiatrie-Pathologie du développement, centre de référence neurogénétique, Hôpital Trousseau AP-HP.SU, FHU I2D2, Paris, France.

Mathieu Anheim (M)

Département de Neurologie, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, Strasbourg.
Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France.
Institut de Génétique et de Biologie Moléculaire et Cellulaire, Illkirch, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH